Should Reckitt Benckiser Group Plc, Royal Dutch Shell Plc And AstraZeneca plc Be In Your 2016 ISA?

Will Reckitt Benckiser Group Plc (LON: RB), Royal Dutch Shell Plc (LON: RDSB) and AstraZeneca plc (LON: AZN) bring you ISA riches?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

What do Lemsip, Nurofen, Cillit Bang and Durex have in common? That’s right, they’re all made by Reckitt Benckiser (LSE: RB), as are Dettol, Gaviscon, Scholl and a whole host of other household names.

And those are just some that are well-known in the UK. Reckitt Benckiser does more than 90% of its business overseas, with the US market contributing around 25% of its annual turnover. That looks like a pretty safe company to me, and a defensive foundation is something a long-term ISA really needs.

Reckitt Benckiser pays very reliable, if unspectacular, dividends yielding a little over 2% per year. But on top of that, the shares have been making steady progress, with today’s price representing a gain of 11% over one year, 40% over two years, and 114% over five years.

On a P/E in the low-20s, the shares are on a higher rating than the FTSE average of around 14, but safety is usually rewarded with higher valuations. And over the next 10 or 20 years or so I see Reckitt Benckiser continuing to reward its shareholders.

Buy Oil?

While getting your timing right really isn’t of key importance for ISA investing, it can be a nice bonus if you happen to pick a low point — and I reckon the case for investing in Royal Dutch Shell (LSE: RDSB) is looking better by the minute. Regardless of the oil price, an investment in one of the big oil producers is likely to serve you well for decades. But now that oil has been looking relatively buoyant for more than a month and is edging up above $40 a barrel, I think the cake could be getting iced.

Shell’s expected dividend yields of around 7.5% won’t be covered by forecast earnings until 2017, but with rival BP having pledged to keep paying its own cash, Shell will be keen to keep it going too — and an oil price recovery is making that look more likely. Oh, and Shell operates a scrip dividend scheme too, so you can take more shares each year instead of cash, and that’s perfect for compounding your rewards.

On top of that, there’s a very strong buy consensus out there among the City’s brokers, and though they might often talk rubbish, I’m with them on this one.

Nicely diverse

Diversification can be key to ISA success, and adding pharmaceuticals giant AstraZeneca (LSE: AZN) would make up a nicely diversified trio. But more important than that, it’s a great long-term investment in its own right.

The company, along with rival GlaxoSmithKline, is still recovering from the expiry a few years ago of some key drug patents and increasing competition from generic products. But the strategy put in place by new boss Pascal Soriot is bearing fruit, and earnings per share could well pass their low point in 2017.

Forecasts put the shares on a forward P/E of 14 at today’s price of 3,900p, and if that’s all it can command at the bottom of an earnings cycle, then it will surely be looking like a screaming bargain once we see a return to growth. Meanwhile, reasonably covered dividend yields of 5% per year should keep investors ticking along quite nicely.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca, GlaxoSmithKline, Reckitt Benckiser, and Royal Dutch Shell. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »

View of Tower Bridge in Autumn
Investing Articles

The FTSE 100 is closing in on 8,000 points! Here’s what I’m buying before it’s too late!

As the FTSE 100 keeps gaining momentum, this Fool is on the lookout for bargains. Here's one stock he'd willingly…

Read more »

Investing Articles

3 ideas to help investors aim for a million-pound Stocks & Shares ISA

The UK has a growing number of Stocks and Shares ISA millionaires, and this plan may be one of the…

Read more »

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »